← Back to patent-cliff list
CAS 1620205-04-0
ethyl 3-(4-chloro-3-nitro-N-(pyridin-2-yl)benzamido)propanoate
Codes: DABI-013
Application context (from source-drug indications)
Venous thromboembolismDabigatran Etexilate MesylateEmbolismDabigatran Etexilate MesylateStrokeDabigatran Etexilate MesylateIschaemic strokeDabigatran Etexilate MesylatePulmonary embolismDabigatran Etexilate MesylateVenous thrombosisDabigatran Etexilate Mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dabigatran Etexilate Mesylate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 3-(pyridin-2-ylamino)propanoate→ethyl 3-(4-(methylamino)-3-nitro-N-(pyridin-2-yl)benzamido)propanoate→4-chloro-3-nitrobenzoic acid→4-chloro-3-nitrobenzoyl chloride→ethyl 3-(4-chloro-3-nitro-N-(pyridin-2-yl)benzamido)propanoate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | Dabigatran etexilate mesylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | ethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | N-(4-cyanophenyl)-Glycine Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.